Evan Loh
Chief Executive Officer at PARATEK PHARMACEUTICALS, INC.
Net worth: 4 457 $ as of 2023-08-30
Evan Loh active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Chief Executive Officer | 2019-06-24 | - |
| Director/Board Member | 2012-04-30 | 2023-09-20 | |
| Chief Operating Officer | 2016-12-31 | 2019-06-24 | |
| Chief Tech/Sci/R&D Officer | 2012-04-30 | 2019-06-24 | |
| President | 2012-04-30 | 2019-06-24 | |
| Sales & Marketing | - | - | |
| EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 2017-09-17 | - |
| Independent Dir/Board Member | 2017-09-17 | - | |
Adaptive Phage Therapeutics, Inc.
 Adaptive Phage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD. | Director/Board Member | 2021-06-28 | - |
Career history of Evan Loh
Former positions of Evan Loh
| Companies | Position | Start | End |
|---|---|---|---|
| WINDTREE THERAPEUTICS, INC. | Director/Board Member | 2021-02-02 | 2022-06-06 |
| Independent Dir/Board Member | 2021-02-02 | 2022-06-06 | |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Director/Board Member | 2012-01-31 | 2017-06-30 |
| Independent Dir/Board Member | 2012-01-31 | 2017-06-30 | |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 2009-09-30 | 2011-12-31 |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Chief Tech/Sci/R&D Officer | 2006-12-31 | 2009-09-30 |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Chairman | - | - |
| Chief Tech/Sci/R&D Officer | - | - | |
| Perelman School of Medicine | Corporate Officer/Principal | - | - |
| ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Evan Loh
| Harvard Medical School | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Statistics
International
| United States | 15 |
Operational
| Director/Board Member | 7 |
| Chief Tech/Sci/R&D Officer | 5 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 10 |
| Consumer Services | 4 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| WINDTREE THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
Antimicrobials Working Group
 Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Commercial Services |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD. | Commercial Services |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
- Stock Market
- Insiders
- Evan Loh
- Experience
